Assessments of CYP ‐Inhibition‐Based Drug–Drug Interactions Between Tofacitinib and Lipid‐Lowering Agents in Rats Both In Vitro and In Vivo
Pharmacology Research & Perspectives · 2025
DOI: 10.1002/prp2.70127 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2025. Verfasst von Hang Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Peking University Fifth School of Clinical Medicine, The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Institute of Geriatric Medici…. Hauptthemen laut MEDLINE: Pyrimidines, Piperidines, Lovastatin, Simvastatin. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National High Level Hospital Clinical Research Funding, National Key R&D Program of China, CAMS Innovation Fund for Medical Sciences.
Abstract (Originalsprache)
Tofacitinib is a widely used medication for the treatment of arthritis. It has been reported that some patients experience abnormal cholesterol levels following treatment, leading to recommendations for the coadministration of lipid‐lowering drugs such as statins. In this study, we investigated the potential drug–drug interactions between tofacitinib and the statins simvastatin and lovastatin. In the in vitro experiments, rat liver microsomes were employed to evaluate the inhibitory effects of lipid‐lowering agents on the metabolism of tofacitinib, with the primary metabolite M8 analyzed using ultra‐performance liquid chromatography–tandem mass spectrometry. The results showed that simvastatin and lovastatin significantly inhibited the metabolism of tofacitinib, with IC 50 values of 5.837 and 10.68 μM, respectively. For the in vivo pharmacokinetic studies, Sprague–Dawley rats were pretreated with simvastatin or lovastatin via oral gavage for 7 days before the oral gavage of tofacitinib. This pretreatment led to an increased area under the concentration–time curve of tofacitinib, suggesting that a potential reduction in the first metabolism and/or systemic clearance takes place. These findings demonstrate significant interactions between tofacitinib and certain lipid‐lowering agents in the rat model, particularly simvastatin and lovastatin, both in vitro and in vivo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Peking University Fifth School of Clinical Medicine, The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Cen…
- Laboratory of Clinical Pharmacy, The Sixth Affiliated Hospital of Wenzhou Medical University, The People's Hospital of Lishui, Lishui, China.
ORCID-Profile: Hang Yang, Shuanghu Wang, Dapeng Dai
Förderung
- National High Level Hospital Clinical Research Funding
- National Key R&D Program of China
- CAMS Innovation Fund for Medical Sciences
- National Key Research and Development Program of China
Zitieren
APA
Yang, H., Wang, S., Zhou, Q., Geng, P., Lu, Z., Lin, Q., Chen, C., Zhou, Y., Cai, J., & Dai, D. (2025). Assessments of CYP ‐Inhibition‐Based Drug–Drug Interactions Between Tofacitinib and Lipid‐Lowering Agents in Rats Both In Vitro and In Vivo. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70127
Vancouver
Yang H, Wang S, Zhou Q, Geng P, Lu Z, Lin Q, et al. Assessments of CYP ‐Inhibition‐Based Drug–Drug Interactions Between Tofacitinib and Lipid‐Lowering Agents in Rats Both In Vitro and In Vivo. Pharmacology Research & Perspectives. 2025. doi:10.1002/prp2.70127
BibTeX
@article{Yang2025,
author = {Yang, Hang and Wang, Shuanghu and Zhou, Quan and Geng, Peiwu and Lu, Zebei and Lin, Qinrong and Chen, Chunhong and Zhou, Yunfang and Cai, Jianping and Dai, Dapeng},
title = {Assessments of CYP ‐Inhibition‐Based Drug–Drug Interactions Between Tofacitinib and Lipid‐Lowering Agents in Rats Both In Vitro and In Vivo},
journal = {Pharmacology Research & Perspectives},
year = {2025},
doi = {10.1002/prp2.70127}
}
EUVIMED